CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

被引:0
作者
Na Yang
Caili Zhang
Yingchun Zhang
Yuting Fan
Jing Zhang
Xiaojin Lin
Ting Guo
Yangzuo Gu
Jieheng Wu
Jianmei Gao
Xing Zhao
Zhixu He
机构
[1] Guizhou Medical University (GMU),Tissue Engineering and Stem Cell Experiment Center
[2] Guizhou Medical University,Department of Immunology, College of Basic Medical Sciences
[3] Guizhou Medical University,Department of Biology, School of Basic Medical Sciences
[4] the Affiliated Hospital of Guizhou Medical University,Department of Gynecology
[5] Sichuan University,State Key Laboratory of Biotherapy and Cancer Center
[6] Zunyi Medical University,School of Pharmacy
[7] Chinese Academy of Medical Sciences),Key Laboratory of Adult Stem Cell Translational Research
[8] the Affiliated Hospital of Zunyi Medical University,Department of Pediatrics
来源
Journal of Translational Medicine | / 22卷
关键词
Chimeric antigen receptor; Natural killer cells; Dual targets; mRNA; Acute lymphoblastic leukemia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 213 条
[1]  
Chen Z(2023)The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia Br J Pharmacol 180 1017-1037
[2]  
Xin Q(2019)Passweg JR [Acute lymphoblastic leukemia - diagnosis and therapy] Ther Umsch Rev Ther 76 510-515
[3]  
Wei W(2020)Acute lymphoblastic leukaemia Lancet Lond Engl 395 1146-1162
[4]  
Wu Y(2017)Changes of peripheral blood marrow-derived suppressor cell level after chemotherapy induction remission by VDLP regimen and their relationship with immune system in B-ALL children Zhongguo Shi Yan Xue Ye Xue Za Zhi 25 1611-4
[5]  
Medinger M(2016)Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia Nutr J 15 65-1186
[6]  
Heim D(2021)Toward the cure of acute lymphoblastic leukemia in children in China JCO Glob Oncol 7 1176-41
[7]  
Lengerke C(2018)CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies J Hematol Oncol 11 41-54
[8]  
Halter JP(2019)CAR-T cells beyond CD19, UnCAR-Ted territory Am J Hematol 94 S34-571
[9]  
Malard F(2021)CAR T-cells in acute lymphoblastic leukemia: current results Bull Cancer (Paris) 108 S40-199
[10]  
Mohty M(2018)Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Nat Med 24 563-374